Inmune Bio ( (INMB) ) has released its Q3 earnings. Here is a breakdown of the information Inmune Bio presented to its investors.
Inmune Bio Inc. is a clinical-stage biotechnology company based in Nevada, focusing on developing therapies aimed at treating diseases related to innate immune system dysfunction, with key products targeting Alzheimer’s, depression, and cancer. In its latest quarterly report, Inmune Bio disclosed a significant increase in net loss, reporting a $32.9 million deficit for the nine months ending September 30, 2024, compared to a $21.6 million loss during the same period in 2023. Key financial highlights include a decrease in total assets from $57 million to $52.8 million and a reduction in cash and cash equivalents. Despite the challenging financial performance, the company raised substantial capital through several stock offerings, resulting in an increase in additional paid-in capital. Looking ahead, Inmune Bio faces substantial liquidity challenges, with management exploring various financing strategies to support ongoing operations and mitigate the going concern risk.
